Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Zolbetuximab niche patient target in gastric cancer will limit its potential in Japan, says GlobalData

Astellas Pharma recently filed new drug application (NDA) in Japan for zolbetuximab, a novel chimeric immunoglobulin G1 antibody highly specific for Claudin 18 isoform 2 (CLDN18.2) for the first-line treatment of gastric cancer patients. Following approval, the drug is expected to have limited potential in the first-line treatment setting, considering the clinical success of its […]
Read more

FDA approval for Pfizer Talzenna paves way for advanced treatment of gene-mutated metastatic prostate cancer, says GlobalData

Pfizer has received FDA approval for Talzenna, a combination therapy with Xtandi, as a treatment for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. Talzenna becomes the first and only PARP inhibitor approved for use in combination with Xtandi, offering new hope for patients. Sales projections indicate significant growth potential, making […]
Read more

Intercept opportunity to market first-ever NASH therapy diminishes with negative FDA GDAC vote, says GlobalData

The FDA’s Gastrointestinal Drugs Advisory Committee (GDAC) has recently voted against Intercept Pharmaceutical’s new drug application (NDA) for obeticholic acid (OCA) 25 mg oral tablets as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH) on the basis that the benefits did not outweigh the risks. The move will significantly reduce the potential […]
Read more

Obicetrapib holds potential to become first CETP inhibitor to advance to clinical practice, says GlobalData

NewAmsterdam Pharma presented positive data from its Phase II ROSE2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy at the National Lipid Association (NLA) Scientific Sessions 2023. The study demonstrated the efficacy of obicetrapib in combination with ezetimibe resulting in the reduction of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein […]
Read more

FDA approval of subcutaneous Vyvgart tackles one of the unmet needs in myasthenia gravis indication, says GlobalData

Following the news that the FDA has approved Argenx’s subcutaneous formulation of efgartimod alfa, branded as Vyvgart Hytrulo, for use in myasthenia gravis (MG); Barbora Salcman, Neurology Analyst at GlobalData, offers her view: “The approval comes after a period of uncertainty and extends the availability of Vyvgart to acetylcholine receptor autoantibody positive (AChR+) patients diagnosed […]
Read more

EU nod boosts Bimzelx’s profile as innovative interleukin-17 inhibitor therapy, says GlobalData

UCB recently announced the European Commission approval for Bimzelx (bimekizumab), its humanized monoclonal IgG1 antibody, which exerts simultaneous selective inhibition of interleukin 17A (IL-17A) and IL-17F, for adults with active psoriatic arthritis (PsA), and active non-radiographic axial spondyloarthritis (axSpA) who exhibit intolerance to non-steroidal anti-inflammatory drugs. Representing a distinctive mechanism of action as a dual […]
Read more

Healthcare professionals see biosimilars as solution to tackle rising costs, finds GlobalData survey

The healthcare industry continues to face the challenges such as persistent inflation in a post-COVID-19 world. Healthcare professionals (HCPs) believe that biosimilars could provide costs savings for the patients and healthcare systems and their use should be encouraged, according to a survey by  GlobalData, a leading data and analytics company. GlobalData survey, “The Impact of […]
Read more

Study indicating bacterial infection could cause endometriosis suggests antibiotics as potential treatment, says GlobalData

In a study published in Science Translational Medicine, researchers from Nagoya University documented how Fusobacterium may play a key role in spurring the development of endometriosis after the bacterium was detected in over 60% of women with the condition. The findings of the study are encouraging and could point to a potential role for antibiotics as treatment […]
Read more

VALUE-Dx initiative highlights potential for improved respiratory infection diagnostics to decelerate AMR, says GlobalData

VALUE-Dx, a first-of-its-kind Innovative Medicines Initiative (IMI) project which aims to improve the use of antibiotics in community care settings, has recently released preliminary information from its upcoming consensus statement on rapid diagnostic tests (RDT) for acute respiratory tract infections (ARTIs) at a post- European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference. The […]
Read more

Label extension will help Injectafer continue penetrating IV iron therapy market, says GlobalData

Injectafer recently secured approval in the US for improvement in exercise capacity in adults with symptomatic heart failure (HF).  A significant number of chronic HF patients suffer from iron deficiency, and these patients are either not diagnosed or do not receive adequate treatment for iron deficiency. Injectafer’s approval allows potentially iron-deficient patients to better manage […]
Read more
1 … 32 33 34 35 36 … 108